Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)

Phase 2

• Conditions: Urothelium Transitional Cell Carcinoma
• Interventions: Drug: Cabazitaxel; Drug: Vinflunine

• Registration Number: NCT01830231
• Lead Sponsor: Associació per a la Recerca Oncologica, Spain

Brief Summary

Due to limited experience with cabazitaxel in TCCU, the study will be started as a randomised phase II study. The aim of the phase II study is to evaluate if the response rates (CR + PR) are sufficiently high to further study the treatment regimens in a phase III setting.

Detailed Description

Once it is confirmed that the subjects fulfil the eligibility criteria and have signed the informed consent, they will be randomised to receive treatment based on cabazitaxel or vinflunine according to the following study schema:

(Randomize 1:1)

* Cabazitaxel 25 mg/m2 q3w

* Vinflunine 250-320 mg/m2 q3w

Random assignment of treatment will be stratified by the presence of 0 versus 1 of the following unfavourable prognostic risk factors proposed recently by Bellmunt et al. (1):

* Eastern Cooperative Oncology Group (ECOG) PS 1.

* Anaemia with Hb \<10 g/dL.

* Presence of liver metastases.

All patients enrolled in the study will receive a cycle of treatment with the study medication (cabazitaxel or vinflunine) every 21 days until disease progression or intolerable/unacceptable toxicity. Tumour evaluations will be scheduled every 6 weeks until progression

Study Timeline

• Study Start: 2012-10
• Study First Submitted: 2013-04-02
• Study First Submitted QC: 2013-04-10
• Study First Posted: 2013-04-12
• Status Verified: 2014-01
• Last Update Submitted: 2014-01-27
• Last Update Posted: 2014-01-28
• Primary Completion: 2016-11
• Study Completion: 2016-11

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 372

Inclusion Criteria

• Written informed consent

• Histologically confirmed TCCU (urinary bladder, urethra, ureter or renal pelvis). Patients with mixed histology may be enrolled if TCCU is the predominant component (i.e., > 50% of the histopathology sample) with the exception of neuroendocrine or small cell carcinoma.

• Advanced disease defined as a locally advanced tumour considered unresectable (T4b), node involvement in the inguinal area or above the aortic bifurcation (that are considered to be distant nodes and so metastasis) or metastasis in distant organs.

• Patient should have received one prior platinum-based chemotherapy treatment for locally advanced or stage IV TCCU. Prior platinum-based adjuvant or neoadjuvant therapy is allowed if more than 6 months have elapsed since the end of adjuvant or neoadjuvant therapy till tumour relapse.

• At least one measurable tumour lesion (measurable disease, as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria v1.1

• ≥18 years.

• ECOG PS 0 or 1.

• May have no more than ONE of the following unfavourable risk factors:

  1. haemoglobin <10 g/dL
  2. presence of liver metastasis
  3. ECOG PS 1

• Life expectancy of at least 12 weeks.

• Adequate hematologic, hepatic, and renal function, defined by:

• Females of childbearing potential must have a negative serum pregnancy test within 7 days of study entry.

Exclusion Criteria

• Patients that have 2 or more of the following unfavourable risk factors:

  1. Haemoglobin <10 g/L
  2. Liver metastasis
  3. ECOG PS 1.

• Women who are currently pregnant or breast-feeding.

• Any unresolved non-hematologic Adverse Event (AE) grade >1 (Common Toxicity Criteria for Adverse Effects (NCI-CTCAE) Version 4.0) from previous anti-cancer therapy (other than alopecia)

• Patients who had undergone major surgery, radiation therapy or treatment with chemotherapy or any investigational agent within 28 days prior to Study day 1.

• Evidence of severe or uncontrolled systemic disease or any concurrent condition

• History of another neoplasm.

• History of hypersensitivity reactions to taxanes (docetaxel) (cabazitaxel specific criteria), vinca alkaloids (vinflunine specific criteria) or to any of the formulation excipients, including polysorbate 80

• clear evidence or symptoms of central nervous system metastasis (cabazitaxel specific criteria).

• Clinically significant cardiac condition

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cabazitaxel	Cabazitaxel	Cabazitaxel 25 mg/m2 q3w. Cabazitaxel will be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion
Vinflunine	Vinflunine	• Vinflunine will be given intravenously once every 21 days, starting at a dose of: * 320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation * 280 mg/m2 in patients aged \>75 - ≤80 years, and/or with PS 1 and/or prior pelvic radiation, * 250 mg/m2 in patients aged \>80 years.

Primary Outcome Measures

Name	Time	Method
Phase II main objective: to assess the efficacy of cabazitaxel compared to vinflunine in terms of improved objective response rate (ORR) of subjects with metastatic or locally advanced previously treated TCCU.	From date of randomization to disease progression or until 18 months from enrolment.	Efficacy of cabazitaxel compared to vinflunine on terms of improved objective response rate (ORR)
Phase III main objective: To assess the efficacy of cabazitaxel compared to vinflunine in terms of improved overall survival (OS) of subjects with metastatic or locally advanced, previously treated TCCU.	From date of randomization to death from any cause or until 18 months from enrolment.

Secondary Outcome Measures

Name	Time	Method
Phase III secondary objective: safety profile and tolerability of cabazitaxel. It will be determined from the number of Adverse Events reported.	From the date the informed consent is signed up to 30 days after the last dose.
Phase II secondary objective: to assess the efficacy of cabazitaxel compared to vinflunine in terms of improved progression-free survival (PFS) and overall survival (OS).	From randomisation to either documented disease progression or death from any cause or until 18 months from enrolment (whichever occurs earlier)
Phase II secondary objective: safety profile and tolerability of cabazitaxel. It will be determined from the number of Adverse Events reported.	From the date the informed consent is signed up to 30 days after the last dose.
Phase III secondary objective: to assess the efficacy of cabazitaxel compared to vinflunine in terms of improved objetive response rate (ORR) and progression free survival (PFS).	From randomisation to either documented disease progression or death from any cause or until 18 months from enrolment (whichever occurs earlier)

Trial Locations

Locations (20)

St. Antoniusziekenhuis; 🇳🇱 Nieuwegein, Netherlands

Vumc Amsterdam; 🇳🇱 Amsterdam, Netherlands

NKI-AvL; 🇳🇱 Amsterdam, Netherlands

Hospital Clínico Universitario de Santiago; 🇪🇸 Santiago de Compostela, A Coruña, Spain

Erasmus MC Rotterdam; 🇳🇱 Rotterdam, Netherlands

Complejo Hospitalario Universitario A Coruña; 🇪🇸 A Coruña, Spain

Clínica Universidad de Navarra; 🇪🇸 Pamplona, Navarra, Spain

Centro Oncologico de Galica; 🇪🇸 A Coruña, Spain

Hospital del Mar; 🇪🇸 Barcelona, Spain

Hospital Vall d´Hebron; 🇪🇸 Barcelona, Spain

Hospital Clínico San Carlos; 🇪🇸 Madrid, Spain

Hospital San Pedro de Alcántara; 🇪🇸 Cáceres, Spain

Hospital Morales Meseguer; 🇪🇸 Murcia, Spain

Hospital Ramón y Cajal; 🇪🇸 Madrid, Spain

Hospital Universitario 12 de Octubre; 🇪🇸 Madrid, Spain

Hospital Son Llatzer; 🇪🇸 Palma de Mallorca, Spain

Complejo Hospitalario Universitario Ourense. Hospital Santa María Nai; 🇪🇸 Ourense, Spain

Hospital Lzoano Blesa; 🇪🇸 Zaragoza, Spain

Fundación Jiménez Díaz; 🇪🇸 Madrid, Spain

Hospital General Universitario de Elche; 🇪🇸 Elche, Alicante, Spain